Cargando…
Chikungunya Virus: Priority Pathogen or Passing Trend?
Chikungunya virus (CHIKV) is considered a priority pathogen and a major threat to global health. While CHIKV infections may be asymptomatic, symptomatic patients can develop chikungunya fever (CHIKF) characterized by severe arthralgia which often transitions into incapacitating arthritis that could...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058558/ https://www.ncbi.nlm.nih.gov/pubmed/36992153 http://dx.doi.org/10.3390/vaccines11030568 |
_version_ | 1785016660393984000 |
---|---|
author | Montalvo Zurbia-Flores, Gerardo Reyes-Sandoval, Arturo Kim, Young Chan |
author_facet | Montalvo Zurbia-Flores, Gerardo Reyes-Sandoval, Arturo Kim, Young Chan |
author_sort | Montalvo Zurbia-Flores, Gerardo |
collection | PubMed |
description | Chikungunya virus (CHIKV) is considered a priority pathogen and a major threat to global health. While CHIKV infections may be asymptomatic, symptomatic patients can develop chikungunya fever (CHIKF) characterized by severe arthralgia which often transitions into incapacitating arthritis that could last for years and lead to significant loss in health-related quality of life. Yet, Chikungunya fever (CHIKF) remains a neglected tropical disease due to its complex epidemiology and the misrepresentation of its incidence and disease burden worldwide. Transmitted to humans by infected Aedes mosquitoes, CHIKV has dramatically expanded its geographic distribution to over 100 countries, causing large-scale outbreaks around the world and putting more than half of the population of the world at risk of infection. More than 50 years have passed since the first CHIKV vaccine was reported to be in development. Despite this, there is no licensed vaccine or antiviral treatments against CHIKV to date. In this review, we highlight the clinical relevance of developing chikungunya vaccines by discussing the poor understanding of long-term disease burden in CHIKV endemic countries, the complexity of CHIKV epidemiological surveillance, and emphasising the impact of the global emergence of CHIKV infections. Additionally, our review focuses on the recent progress of chikungunya vaccines in development, providing insight into the most advanced vaccine candidates in the pipeline and the potential implications of their roll-out. |
format | Online Article Text |
id | pubmed-10058558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100585582023-03-30 Chikungunya Virus: Priority Pathogen or Passing Trend? Montalvo Zurbia-Flores, Gerardo Reyes-Sandoval, Arturo Kim, Young Chan Vaccines (Basel) Review Chikungunya virus (CHIKV) is considered a priority pathogen and a major threat to global health. While CHIKV infections may be asymptomatic, symptomatic patients can develop chikungunya fever (CHIKF) characterized by severe arthralgia which often transitions into incapacitating arthritis that could last for years and lead to significant loss in health-related quality of life. Yet, Chikungunya fever (CHIKF) remains a neglected tropical disease due to its complex epidemiology and the misrepresentation of its incidence and disease burden worldwide. Transmitted to humans by infected Aedes mosquitoes, CHIKV has dramatically expanded its geographic distribution to over 100 countries, causing large-scale outbreaks around the world and putting more than half of the population of the world at risk of infection. More than 50 years have passed since the first CHIKV vaccine was reported to be in development. Despite this, there is no licensed vaccine or antiviral treatments against CHIKV to date. In this review, we highlight the clinical relevance of developing chikungunya vaccines by discussing the poor understanding of long-term disease burden in CHIKV endemic countries, the complexity of CHIKV epidemiological surveillance, and emphasising the impact of the global emergence of CHIKV infections. Additionally, our review focuses on the recent progress of chikungunya vaccines in development, providing insight into the most advanced vaccine candidates in the pipeline and the potential implications of their roll-out. MDPI 2023-03-01 /pmc/articles/PMC10058558/ /pubmed/36992153 http://dx.doi.org/10.3390/vaccines11030568 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Montalvo Zurbia-Flores, Gerardo Reyes-Sandoval, Arturo Kim, Young Chan Chikungunya Virus: Priority Pathogen or Passing Trend? |
title | Chikungunya Virus: Priority Pathogen or Passing Trend? |
title_full | Chikungunya Virus: Priority Pathogen or Passing Trend? |
title_fullStr | Chikungunya Virus: Priority Pathogen or Passing Trend? |
title_full_unstemmed | Chikungunya Virus: Priority Pathogen or Passing Trend? |
title_short | Chikungunya Virus: Priority Pathogen or Passing Trend? |
title_sort | chikungunya virus: priority pathogen or passing trend? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058558/ https://www.ncbi.nlm.nih.gov/pubmed/36992153 http://dx.doi.org/10.3390/vaccines11030568 |
work_keys_str_mv | AT montalvozurbiafloresgerardo chikungunyavirusprioritypathogenorpassingtrend AT reyessandovalarturo chikungunyavirusprioritypathogenorpassingtrend AT kimyoungchan chikungunyavirusprioritypathogenorpassingtrend |